Meeting
2022 ASCO Annual Meeting
Rationale and design of phase 1 FTIH study of FOXP3 antisense oligonucleotide AZD8701 in patients with selected advanced solid tumors.
Presenter
Michele Petruzzelli
AstraZeneca
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
New Targets and New Technologies (non-IO)
Clinical Trial Registration Number
NCT04504669
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS3166)
DOI
10.1200/JCO.2022.40.16_suppl.TPS3166
Abstract #
TPS3166
Poster Bd #
150a
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
A phase 1 study of REGN6569, a GITR mAb, in combination with cemiplimab in patients (pts) with advanced solid tumor malignancies: Initial dose-escalation results.
Speaker: Nehal J. Lakhani, MD, PhD
Speaker: Suthee Rapisuwon, MD
Videos & Slides
2024 ASCO Annual Meeting
Phase 1 study of BA3071, an anti–CTLA-4 conditionally active biologic, in combination with nivolumab in advanced solid tumors.
Speaker: Jacob Stephen Thomas, MD
Videos & Slides
2024 ASCO Annual Meeting
Preliminary results from a phase I expansion study of ZG005, a bispecific antibody targeting TIGIT and PD-1, as monotherapy in patients with advanced solid tumors.
Speaker: Shukui Qin, MD